XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

Source: 
Seeking Alpha
snippet: 

XBiotech (NASDAQ:XBIT) inks an agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.